ESSA Pharma Inc.

10/21/2023 | Press release | Distributed by Public on 10/21/2023 07:06

Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer[...]